-
1 Comment
Soleno Therapeutics, Inc is currently in a long term downtrend where the price is trading 38.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Soleno Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 80.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 35.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Soleno Therapeutics, Inc gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 19M |
|---|---|
| PE Ratio | None |
| Target Price | 6 |
| Dividend Yield | 0.0% |
| Beta | 0.24 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6XC1.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
